Cyclotriazadisulfonamides: Promising new CD4-targeted anti-HIV drugs

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 2, 2005, Pages 270-272

  Vermeire, Kurt ^a   Schols, Dominique ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

CADA; CD4 receptor; Down modulation; HIV entry; Microbicides

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); 9 BENZYL 3 METHYLENE 1,5 DI 4 TOLUENESULFONYL 1,5,9 TRIAZACYCLODODECANE; ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CYCLOTRIAZADISULFONAMIDE DERIVATIVE; DELAVIRDINE; ENFUVIRTIDE; GALANTHUS NIVALIS EXTRACT; GLYCOPROTEIN GP 41; HERBACEOUS AGENT; INDINAVIR; LAMIVUDINE; LOPINAVIR; LYMPHOCYTE ANTIGEN RECEPTOR; NELFINAVIR; NEVIRAPINE; PLANT LECTIN; PROTEIN KINASE C; RITONAVIR; SAQUINAVIR; SULFONAMIDE; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS RECEPTOR; ZALCITABINE; ZIDOVUDINE;

ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; CORRELATION ANALYSIS; DENDRITIC CELL; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; GALANTHUS; GALANTHUS NIVALIS; GENE TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MONOCYTE; NONHUMAN; STRUCTURE ANALYSIS; T LYMPHOCYTE; TARGET CELL; VIRUS STRAIN; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; ANTIGENS, CD4; HETEROCYCLIC COMPOUNDS; HIV INFECTIONS; HIV-1; HUMANS;

EID: 23844469822     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki208     Document Type: Article

References (20)

1. Chan DC, Kim PS. HIV entry and its inhibition. Cell 1998; 93: 681-4.
2. Vermeire K, Zhang Y, Princen K et al. CADA inhibits human immunodeficiency virus and human herpesvirus-7 replication by downmodulation of the cellular CD4 receptor. Virology 2002; 302: 342-53.
3. Vermeire K, Princen K, Hatse S et al. CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. AIDS2004; 18: 2115-25.
4. Vermeire K, Schols D. Specific CD4 down-modulating compounds with potent anti-HIV activity. J Leukoc Biol 2003; 74: 667-75.
5. Vermeire K, Bell TW, Choi HJ et al. The anti-HIV potency of cyclotriazadisulfonamide analogs is directly correlated with their ability to down-modulate the CD4 receptor. Mol Pharmacol 2003; 63: 203-10.
6. Vermeire K, Van Laethem K, Vandamme AM et al. Resistance profile of human immunodeficiency virus to CADA, a novel HIV inhibitor that targets the cellular CD4 receptor. In: Abstracts of the Eighteenth International Conference on Antiviral Research, Barcelona, Spain, 2005:. Abstract 34, p. A43. Antiviral Res 2005; 65: A43.
7. Kwong PD, Wyatt R, Sattentau QJ et al. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J Virol 2000; 74: 1961-72.
8. Layne SP, Merges MJ, Dembo M et al. HIV requires multiple gp120 molecules for CD4-mediated infection. Nature 1990; 346: 277-9.
9. Chesebro B, Buller R, Portis J et al. Failure of human immunodeficiency virus entry and infection in CD4-positive human brain and skin cells. J Virol 1990; 64: 215-21.
10. Kabat D, Kozak SL, Wehrly K et al. Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J Virol 1994; 68: 2570-7.
11. Kozak SL, Platt EJ, Madani N et al. CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. J Virol 1997; 71: 873-82.
12. Platt EJ, Madani N, Kozak SL et al. Infectious properties of human immunodeficiency virus type 1 mutants with distinct affinities for the CD4 receptor. J Virol 1997; 71: 883-90.
13. Platt EJ, Wehrly K, Kuhmann SE et al. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 1998; 72: 2855-64.
14. Platt EJ, Kozak SL, Kabat D. Critical role of enhanced CD4 affinity in laboratory adaptation of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2000; 16: 871-82.
15. Hoffman TL, LaBranche CC, Zhang W et al. Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Proc Natl Acad Sci USA 1999; 96: 6359-64.
16. Edwards TG, Hoffman TL, Baribaud F et al. Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein. J Virol 2001; 75: 5230-9.
17. Kolchinsky P, Kiprilov E, Sodroski J. Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J Virol 2001; 75: 2041-50.
18. Mauck C, Rosenberg Z, Van Damme L. Recommendations for the clinical development of topical microbicides: An update. AIDS 2001; 15: 857-68.
19. Hu Q, Frank I, Williams V et al. Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J Exp Med 2004; 199: 1065-75.
20. Kuritzkes DR, Jacobson J, Powderly WG et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 2004; 189: 286-91.